Literature DB >> 10760082

cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway.

T Yamaguchi1, J C Pelling, N T Ramaswamy, J W Eppler, D P Wallace, S Nagao, L A Rome, L P Sullivan, J J Grantham.   

Abstract

BACKGROUND: : Cellular proliferation is a key factor in the enlargement of renal cysts in autosomal dominant polycystic kidney disease (ADPKD). We determined the extent to which adenosine 3':5'-cyclic monophosphate (cAMP) may regulate the in vitro proliferation of cyst epithelial cells derived from human ADPKD cysts.
METHODS: : Epithelial cells from cysts of individuals with ADPKD and from normal human kidney cortex (HKC) of individuals without ADPKD were cultured. The effects of agonists and inhibitors on the rate of cellular proliferation and the activation of extracellular signal-regulated kinase (ERK1/2) were determined.
RESULTS: : 8-Br-cAMP (100 micromol/L) stimulated the proliferation of cells from eight different ADPKD subjects to 99.0% above baseline; proliferation was inhibited by protein kinase A (PKA) antagonists H-89 (97%) and Rp-cAMP (90%). Forskolin (10 micromol/L), which activates adenylyl cyclase, increased proliferation 124%, and receptor-mediated agonists arginine vasopressin, desmopressin, secretin, vasoactive intestinal polypeptide, and prostaglandin E2 stimulated proliferation 54.2, 56.3, 46.7, 37.1, and 48.3%, respectively. The mitogen extracellular kinase (MEK) inhibitor PD98059 completely inhibited ADPKD cell proliferation in response to cAMP agonists, but genistein, a receptor tyrosine kinase inhibitor, did not block cAMP-dependent proliferation. cAMP agonists increased the activity of ERK above control levels within five minutes. In contrast to ADPKD, proliferation and ERK activity of cells derived from normal HKC were not stimulated by cAMP agonists, although electrogenic Cl- secretion was increased by these agonists in both ADPKD and HKC cell monolayers.
CONCLUSIONS: : We conclude that cAMP agonists stimulate the proliferation of ADPKD but not HKC epithelial cells through PKA activation of the ERK pathway at a locus distal to receptor tyrosine kinase. We suggest that the adenylyl cyclase signaling pathway may have a unique role in determining the rate of cyst enlargement in ADPKD through its actions to stimulate cellular proliferation and transepithelial solute and fluid secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760082     DOI: 10.1046/j.1523-1755.2000.00991.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  124 in total

Review 1.  Polycystic kidney disease: In danger of being X-rated?

Authors:  J J Grantham; J P Calvet
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Inhibition of the P2X7 receptor reduces cystogenesis in PKD.

Authors:  Ming-Yang Chang; Jenn-Kan Lu; Ya-Chung Tian; Yung-Chang Chen; Cheng-Chieh Hung; Yi-Hui Huang; Yau-Hung Chen; Mai-Szu Wu; Chih-Wei Yang; Yi-Chuan Cheng
Journal:  J Am Soc Nephrol       Date:  2011-06-02       Impact factor: 10.121

3.  New insights into ciliary function: kidney cysts and photoreceptors.

Authors:  James P Calvet
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

4.  Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.

Authors:  Burton M Wice; Songyan Wang; Dan L Crimmins; Kelly A Diggs-Andrews; Matthew C Althage; Eric L Ford; Hung Tran; Matthew Ohlendorf; Terry A Griest; Qiuling Wang; Simon J Fisher; Jack H Ladenson; Kenneth S Polonsky
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

Review 5.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 6.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 7.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Authors:  Markus M Rinschen; Bernhard Schermer; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

9.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

10.  Src inhibition ameliorates polycystic kidney disease.

Authors:  William E Sweeney; Rodo O von Vigier; Philip Frost; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.